Methylphenidate, used to improve cognitive impairment in pediatric cancer survivors, is generally well tolerated, according to a study in Pediatrics that looked at two doses of the drug in a group of 103 childhood cancer survivors. They noted a subgroup of patients was at increased risk of side effects and might need a lower dosage.

Related Summaries